IDEAYA Biosciences, Inc. (IDYA) — Financial statements
Income statement, balance sheet, and cash flow for IDEAYA Biosciences, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 219↑3024.4% | 7↓70.1% | 23↓54.1% | 51↑82.3% | 28 | |
| Cost of Revenue | 5↑19.8% | 4↓4.3% | 4↑90.8% | 2↑21.8% | 2 | |
| Gross Profit | 214↑6663.0% | 3↓83.7% | 19↓60.3% | 49↑86.3% | 26 | |
| Operating Expenses | ||||||
| R&D Expenses | 315↑6.8% | 295↑127.5% | 130↑44.6% | 90↑54.0% | 58 | |
| General & Administrative Expenses | 63 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 63↑78.5% | 35↑46.0% | 24↑11.5% | 22↑18.9% | 18 | |
| Other Expenses | -5 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 373↑13.1% | 330↑114.6% | 154↑38.2% | 111↑45.6% | 76 | |
| Total Costs & Expenses | 378↑13.2% | 334↑111.6% | 158↑39.1% | 113↑45.0% | 78 | |
| Operating Results | ||||||
| Operating Income | -159↑51.3% | -327↓143.2% | -134↓115.1% | -63↓24.3% | -50 | |
| Depreciation & Amortization | 5↑19.8% | 4↓4.3% | 4↑90.8% | 2↑21.8% | 2 | |
| EBITDA | -155↑42.8% | -271↓148.4% | -109↓92.7% | -57↓17.7% | -48 | |
| EBIT | -159↑42.0% | -274↓143.0% | -113↓92.6% | -59↓17.9% | -50 | |
| Interest & Other Income | ||||||
| Net Interest Income | 46↓13.1% | 52↑144.5% | 21↑458.0% | 4↑660.3% | 0.51 | |
| Interest Income | 46↓13.1% | 52↑144.5% | 21↑458.0% | 4↑660.3% | 0.51 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -52↓144.5% | -21↓458.0% | -4↓660.3% | -0.51 | |
| Other Income / Expenses | 46↓13.1% | 52↑144.5% | 21↑458.0% | 4↑660.3% | 0.51 | |
| Income Before Tax | -114↑58.6% | -274↓143.0% | -113↓92.6% | -59↓17.9% | -50 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -114↑58.6% | -274↓143.0% | -113↓92.6% | -59↓17.9% | -50 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -114↑58.6% | -274↓143.0% | -113↓92.6% | -59↓17.9% | -50 | |
| Bottom-Line Net Income | -114↑58.6% | -274↓143.0% | -113↓92.6% | -59↓17.9% | -50 | |
| EPS (Basic) | -1.28↑61.9% | -3.36↓71.4% | -1.96↓38.0% | -1.42↓0.7% | -1.41 | |
| EPS (Diluted) | -1.28↑61.9% | -3.36↓71.4% | -1.96↓38.0% | -1.42↓0.7% | -1.41 | |
| Weighted Average Shares | 88↑8.3% | 82↑42.0% | 58↑38.8% | 41↑17.6% | 35 | |
| Weighted Average Diluted Shares | 88↑8.3% | 82↑42.0% | 58↑38.8% | 41↑17.6% | 35 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.